A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre-B Acute Lymphoblastic Leukemia.
Document Type
Article
Publication Date
5-1-2023
Identifier
DOI: 10.1097/MPH.0000000000002613
Abstract
BACKGROUND: Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of cancer therapy. After alkylating agents, this typically occurs years after completion of therapy. Treatment of t-MDS in pediatrics is an allogeneic stem cell transplant, however, the prognosis remains poor.
OBSERVATIONS: This case demonstrates t-MDS developing in a patient receiving treatment for pre-B acute lymphoblastic leukemia. This patient was treated with a combination of hematopoietic stem cell transplant and hypomethylating agents.
CONCLUSIONS: These agents should be considered for use in patients with t-MDS, before transplant to limit additional chemotherapy and as maintenance therapy post-transplant to reduce the risk of relapse.
Journal Title
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology
Volume
45
Issue
4
First Page
518
Last Page
521
MeSH Keywords
Humans; Child; Hematopoietic Stem Cell Transplantation; Myelodysplastic Syndromes; Stem Cell Transplantation; Prognosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute
Keywords
Hematopoietic Stem Cell Transplantation; Myelodysplastic Syndromes; Stem Cell Transplantation; Prognosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Acute Myeloid Leukemia, Myeloid, Acute
Recommended Citation
McElroy S, Myers GD, Flatt T. A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre-B Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2023;45(4):e518-e521. doi:10.1097/MPH.0000000000002613
COinS
